Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EPS (Basic): 2009-2024

Historic EPS (Basic) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to -$1.04.

  • Ani Pharmaceuticals' EPS (Basic) rose 193.70% to $1.19 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.71, marking a year-over-year increase of 410.91%. This contributed to the annual value of -$1.04 for FY2024, which is 220.93% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported EPS (Basic) of -$1.04 as of FY2024, which was down 220.93% from $0.86 recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' EPS (Basic) registered a high of $0.86 during FY2023, and its lowest value of -$3.40 during FY2021.
  • For the 3-year period, Ani Pharmaceuticals' EPS (Basic) averaged around -$1.08, with its median value being -$1.04 (2024).
  • As far as peak fluctuations go, Ani Pharmaceuticals' EPS (Basic) slumped by 468.63% in 2020, and later soared by 128.20% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' EPS (Basic) (Yearly) stood at -$1.88 in 2020, then crashed by 80.85% to -$3.40 in 2021, then grew by 10.29% to -$3.05 in 2022, then surged by 128.20% to $0.86 in 2023, then slumped by 220.93% to -$1.04 in 2024.